Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $14.7M | $22.6M | $49.0M | $89.1M | $140M | $134M |
| Revenue growth | — | 53.9% | 116.9% | 81.8% | 57.1% | -3.9% |
| Gross profit | $1.71M | $4.52M | $21.3M | $53.8M | $98.9M | $103M |
| Gross margin | 11.6% | 20.0% | 43.5% | 60.4% | 70.7% | 76.6% |
| Operating income | -$35.4M | -$52.8M | -$63.3M | -$50.1M | -$36.9M | -$48.2M |
| Operating margin | -241.3% | -233.6% | -129.2% | -56.2% | -26.3% | -35.8% |
| Net income | $27.6M | -$48.7M | -$66.8M | -$48.6M | -$27.5M | -$38.9M |
| Net margin | 187.9% | -215.5% | -136.2% | -54.6% | -19.6% | -29.0% |
| EPS (diluted) | $0.15 | -$3.57 | -$2.41 | -$1.41 | -$0.71 | -$0.95 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$35.2M | -$44.7M | -$58.9M | -$41.6M | -$16.9M | -$15.5M |
| Capital expenditures | $2.54M | $1.94M | $2.39M | $4.81M | $5.44M | $3.83M |
| Free cash flow | -$37.7M | -$46.6M | -$61.2M | -$46.4M | -$22.4M | -$19.3M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $14.0M | $24.4M | $11.8M | $9.69M | $16.7M | $19.9M |
| Total assets | $101M | $193M | $150M | $183M | $319M | $312M |
| Total liabilities | $44.9M | $54.5M | $60.3M | $22.2M | $37.3M | $36.1M |
| Long-term debt | $24.4M | $39.8M | $40.2M | $0.00 | — | — |
| Shareholders' equity | -$431M | $138M | $89.9M | $160M | $281M | $276M |
| Retained earnings | -$431M | -$479M | -$546M | -$595M | -$622M | -$661M |
| Shares (wtd avg diluted) | 5.53M | 13.6M | 27.7M | 34.5M | 38.9M | 40.9M |
Every figure is extracted from RxSight, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.